We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fullgent Genetics (FLGT) Stock Moves -1.28%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Fullgent Genetics (FLGT - Free Report) closed at $56.44, marking a -1.28% move from the previous day. This change was narrower than the S&P 500's 2.77% loss on the day. At the same time, the Dow lost 2.82%, and the tech-heavy Nasdaq lost 0.83%.
Heading into today, shares of the company had lost 8.45% over the past month, lagging the Medical sector's loss of 0.16% and the S&P 500's loss of 1.35% in that time.
Wall Street will be looking for positivity from Fullgent Genetics as it approaches its next earnings report date. This is expected to be May 3, 2022. In that report, analysts expect Fullgent Genetics to post earnings of $4.32 per share. This would mark a year-over-year decline of 34.45%. Our most recent consensus estimate is calling for quarterly revenue of $300.5 million, down 16.4% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.30 per share and revenue of $649.05 million, which would represent changes of -55.43% and -34.61%, respectively, from the prior year.
Any recent changes to analyst estimates for Fullgent Genetics should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 16.06% higher. Fullgent Genetics is currently a Zacks Rank #3 (Hold).
Investors should also note Fullgent Genetics's current valuation metrics, including its Forward P/E ratio of 7.83. Its industry sports an average Forward P/E of 21.41, so we one might conclude that Fullgent Genetics is trading at a discount comparatively.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 163, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Fullgent Genetics (FLGT) Stock Moves -1.28%: What You Should Know
In the latest trading session, Fullgent Genetics (FLGT - Free Report) closed at $56.44, marking a -1.28% move from the previous day. This change was narrower than the S&P 500's 2.77% loss on the day. At the same time, the Dow lost 2.82%, and the tech-heavy Nasdaq lost 0.83%.
Heading into today, shares of the company had lost 8.45% over the past month, lagging the Medical sector's loss of 0.16% and the S&P 500's loss of 1.35% in that time.
Wall Street will be looking for positivity from Fullgent Genetics as it approaches its next earnings report date. This is expected to be May 3, 2022. In that report, analysts expect Fullgent Genetics to post earnings of $4.32 per share. This would mark a year-over-year decline of 34.45%. Our most recent consensus estimate is calling for quarterly revenue of $300.5 million, down 16.4% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.30 per share and revenue of $649.05 million, which would represent changes of -55.43% and -34.61%, respectively, from the prior year.
Any recent changes to analyst estimates for Fullgent Genetics should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 16.06% higher. Fullgent Genetics is currently a Zacks Rank #3 (Hold).
Investors should also note Fullgent Genetics's current valuation metrics, including its Forward P/E ratio of 7.83. Its industry sports an average Forward P/E of 21.41, so we one might conclude that Fullgent Genetics is trading at a discount comparatively.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 163, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.